<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01859988</url>
  </required_header>
  <id_info>
    <org_study_id>R668-AD-1021</org_study_id>
    <nct_id>NCT01859988</nct_id>
  </id_info>
  <brief_title>Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult
      participants with moderate-to-severe atopic dermatitis (AD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Investigator's Global Assessment (IGA) Response at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a static 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as a non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved IGA Score Reduction of ≥2 at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic success is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score reduction from baseline of ≥2 points at Week 16 were reported. Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as a non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Peak Weekly Averaged Pruritus Numerical Rating Scores (NRS) From Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Pruritus NRS is an assessment tool that is used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Peak Weekly Averaged Pruritus NRS From Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Pruritus NRS is an assessment tool that is used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in EASI Score From Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in SCORing Atopic Dermatitis (SCORAD) Scores From Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in SCORAD Scores From Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in EASI Score (EASI-50, EASI-75 and EASI-90 Respectively) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50, EASI-75 and EASI-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% overall improvement in EASI score respectively from baseline to Week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in SCORAD Score (SCORAD-50, SCORAD-75 and SCORAD-90 Respectively) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). SCORAD-50, SCORAD-75 and SCORAD-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% overall improvement in SCORAD score respectively from baseline to Week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Patient Oriented Eczema Measure (POEM) Scores From Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life [QOL]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in POEM Scores From Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life [QOL]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations, and Lichenification) From Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0=none, 1=mild, 2=moderate and 3=severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in GISS Cumulative Score From Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none,1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">380</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Placebo qw</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection every week (qw) from Week 1 to Week 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dupilumab 300 mg qw</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dupilumab 300 mg q2w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dupilumab 200 mg q2w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dupilumab 300 mg q4w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab every 4 weeks (q4w) and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dupilumab 100 mg q4w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <arm_group_label>Dupilumab 300 mg qw</arm_group_label>
    <arm_group_label>Dupilumab 300 mg q2w</arm_group_label>
    <arm_group_label>Dupilumab 200 mg q2w</arm_group_label>
    <arm_group_label>Dupilumab 300 mg q4w</arm_group_label>
    <arm_group_label>Dupilumab 100 mg q4w</arm_group_label>
    <other_name>REGN668</other_name>
    <other_name>SAR231893</other_name>
    <other_name>Dupixent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo qw</arm_group_label>
    <arm_group_label>Dupilumab 300 mg q2w</arm_group_label>
    <arm_group_label>Dupilumab 200 mg q2w</arm_group_label>
    <arm_group_label>Dupilumab 300 mg q4w</arm_group_label>
    <arm_group_label>Dupilumab 100 mg q4w</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The inclusion criteria included, but were not limited to, the following:

          1. Chronic Atopic Dermatitis that had been present for at least 3 years

          2. History of inadequate response to out-patient treatment with topical medications, or
             for whom topical treatments were otherwise inadvisable (e.g, because of important side
             effects or safety risks)

          3. Willing and able to comply with all clinic visits and study-related procedures

        The exclusion criteria included, but were not limited to, the following:

          1. Prior treatment with dupilumab (REGN668/SAR231893)

          2. Presence of certain laboratory abnormalities at the screening visit

          3. Treatment with an investigational drug within 8 weeks of baseline visit

          4. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit

          5. Certain other treatments and medical procedures undertaken within a particular time
             frame prior to the baseline visit

          6. Known history of human immunodeficiency virus (HIV) infection

          7. History of malignancy within 5 years before the baseline visit (with certain
             exceptions)

          8. Planned surgical procedure during the length of the study

          9. High risk of parasite infection

         10. Any other medical or psychological condition that in the opinion of the investigator
             or the sponsor's medical monitor, would place the participants at risk, interfere with
             participation in the study or interfere with interpretation of study results

         11. Pregnant or breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver (2 locations)</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Hyacinthe</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kutná Hora</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nachod</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Svitavy</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Usti nad Labem</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dülmen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt/ Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt/Main, Hessen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gera</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mahlow</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muenster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osnabruck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Borsod-Abauj-Zemplen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaposvár</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tolna</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo, Bunkyo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo, Chiyoda-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo, Nakano-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo, Nerima-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo, Shibuya-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo, Shinagawa-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo, Shinjuku-ku (2 locations)</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo, Suginami-ku (2 locations)</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk (2 locations)</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw (2 locations)</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <results_reference>
    <citation>Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NM, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016 Jan 2;387(10013):40-52. doi: 10.1016/S0140-6736(15)00388-8. Epub 2015 Oct 8.</citation>
    <PMID>26454361</PMID>
  </results_reference>
  <results_reference>
    <citation>Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NM, Pirozzi G, Mastey V. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016 Mar;74(3):491-8. doi: 10.1016/j.jaad.2015.10.043. Epub 2016 Jan 14.</citation>
    <PMID>26777100</PMID>
  </results_reference>
  <results_reference>
    <citation>Simpson EL, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L, Wu R, Ardeleanu M, Graham NMH, Pirozzi G, Sutherland ER, Mastey V. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol. 2016 Sep;75(3):506-515. doi: 10.1016/j.jaad.2016.04.054. Epub 2016 Jun 4.</citation>
    <PMID>27268421</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2013</study_first_submitted>
  <study_first_submitted_qc>May 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2013</study_first_posted>
  <results_first_submitted>July 26, 2017</results_first_submitted>
  <results_first_submitted_qc>July 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2017</results_first_posted>
  <disposition_first_submitted>April 1, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 1, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 21, 2015</disposition_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 95 study sites in 7 countries. A total of 452 participants were screened between 15 May 2013 and 10 January 2014. 380 participants were randomized and 379 were treated. 72 participants were screen failures mainly due to exclusion criteria met and inclusion criteria not met.</recruitment_details>
      <pre_assignment_details>Randomization was stratified by disease severity (moderate Investigator's global assessment [IGA] = 3 versus severe IGA = 4 atopic dermatitis) and region (Japan versus rest of world). Assignment to arms was done centrally in 1:1:1:1:1:1 ratio for Dupilumab (300 mg qw; 300 mg q2w; 200 mg q2w; 300 mg q4w and 100 mg q4w) and Placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dupilumab 300 mg qw</title>
          <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection every week (qw) from Week 1 to Week 15.</description>
        </group>
        <group group_id="P2">
          <title>Dupilumab 300 mg q2w</title>
          <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 15.</description>
        </group>
        <group group_id="P3">
          <title>Dupilumab 200 mg q2w</title>
          <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
        </group>
        <group group_id="P4">
          <title>Dupilumab 300 mg q4w</title>
          <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab every 4 weeks (q4w) and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
        </group>
        <group group_id="P5">
          <title>Dupilumab 100 mg q4w</title>
          <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="65"/>
                <participants group_id="P5" count="65"/>
                <participants group_id="P6" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="65"/>
                <participants group_id="P5" count="65"/>
                <participants group_id="P6" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="42"/>
                <participants group_id="P6" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline population included safety analysis set (SAF) that included all randomized participants who received any investigational product and analyzed as treated. One participant randomized into Dupilumab 200 mg q2w arm was not treated and hence, excluded from the baseline population.</population>
      <group_list>
        <group group_id="B1">
          <title>Dupilumab 300 mg qw</title>
          <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.</description>
        </group>
        <group group_id="B2">
          <title>Dupilumab 300 mg q2w</title>
          <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
        </group>
        <group group_id="B3">
          <title>Dupilumab 200 mg q2w</title>
          <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
        </group>
        <group group_id="B4">
          <title>Dupilumab 300 mg q4w</title>
          <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
        </group>
        <group group_id="B5">
          <title>Dupilumab 100 mg q4w</title>
          <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="61"/>
            <count group_id="B4" value="65"/>
            <count group_id="B5" value="65"/>
            <count group_id="B6" value="61"/>
            <count group_id="B7" value="379"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.2" spread="10.74"/>
                    <measurement group_id="B2" value="39.4" spread="12.06"/>
                    <measurement group_id="B3" value="35.8" spread="14.90"/>
                    <measurement group_id="B4" value="36.8" spread="10.77"/>
                    <measurement group_id="B5" value="36.6" spread="11.55"/>
                    <measurement group_id="B6" value="37.2" spread="13.10"/>
                    <measurement group_id="B7" value="37.0" spread="12.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16</title>
        <description>The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Full analysis set (FAS) that included all randomized participants who received at least 1 dose of study drug. Here, number of participants analyzed = participants with EASI score assessment at specified time-point. Efficacy data was set to missing after use of rescue medication. Missing values imputed by last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Dupilumab 300 mg qw</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.</description>
          </group>
          <group group_id="O2">
            <title>Dupilumab 300 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O3">
            <title>Dupilumab 200 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O4">
            <title>Dupilumab 300 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O5">
            <title>Dupilumab 100 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16</title>
          <description>The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.</description>
          <population>Full analysis set (FAS) that included all randomized participants who received at least 1 dose of study drug. Here, number of participants analyzed = participants with EASI score assessment at specified time-point. Efficacy data was set to missing after use of rescue medication. Missing values imputed by last observation carried forward (LOCF).</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-75.5" spread="26.86"/>
                    <measurement group_id="O2" value="-70.5" spread="35.09"/>
                    <measurement group_id="O3" value="-67.4" spread="31.97"/>
                    <measurement group_id="O4" value="-64.9" spread="37.21"/>
                    <measurement group_id="O5" value="-46.7" spread="41.96"/>
                    <measurement group_id="O6" value="-20.2" spread="46.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>LS mean and standard error were obtained using analysis of covariance (ANCOVA) model with treatment and randomization strata (moderate vs severe;Japan vs rest of world) and relevant baseline values as covariates. Multiplicity was controlled using hierarchical testing procedure:highest dose vs. placebo was tested first. Comparison order was 300 mg qw,300 mg q2w,200 mg q2w,300 mg q4w &amp; 100 mg q4w, vs placebo respectively. Testing continues only if previous comparison was statistically significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least square (LS) mean difference</param_type>
            <param_value>-55.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.74</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.9</ci_lower_limit>
            <ci_upper_limit>-42.4</ci_upper_limit>
            <estimate_desc>Dupilumab 300 mg qw vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-50.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.67</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.3</ci_lower_limit>
            <ci_upper_limit>-37.0</ci_upper_limit>
            <estimate_desc>Dupilumab 300 mg q2w vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-47.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.6</ci_lower_limit>
            <ci_upper_limit>-34.1</ci_upper_limit>
            <estimate_desc>Dupilumab 200 mg q2w vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-45.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.5</ci_lower_limit>
            <ci_upper_limit>-32.3</ci_upper_limit>
            <estimate_desc>Dupilumab 300 mg q4w vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-26.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.8</ci_lower_limit>
            <ci_upper_limit>-13.7</ci_upper_limit>
            <estimate_desc>Dupilumab 100 mg q4w vs Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Investigator's Global Assessment (IGA) Response at Week 16</title>
        <description>IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a static 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as a non-responders.</description>
        <time_frame>Week 16</time_frame>
        <population>Analysis was performed on FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupilumab 300 mg qw</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.</description>
          </group>
          <group group_id="O2">
            <title>Dupilumab 300 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O3">
            <title>Dupilumab 200 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O4">
            <title>Dupilumab 300 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O5">
            <title>Dupilumab 100 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Investigator's Global Assessment (IGA) Response at Week 16</title>
          <description>IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a static 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as a non-responders.</description>
          <population>Analysis was performed on FAS.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="21.95" upper_limit="46.34"/>
                    <measurement group_id="O2" value="29.7" lower_limit="18.91" upper_limit="42.42"/>
                    <measurement group_id="O3" value="27.9" lower_limit="17.15" upper_limit="40.83"/>
                    <measurement group_id="O4" value="21.5" lower_limit="12.31" upper_limit="33.49"/>
                    <measurement group_id="O5" value="12.3" lower_limit="5.47" upper_limit="22.82"/>
                    <measurement group_id="O6" value="1.6" lower_limit="0.04" upper_limit="8.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved IGA Score Reduction of ≥2 at Week 16</title>
        <description>IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic success is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score reduction from baseline of ≥2 points at Week 16 were reported. Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as a non-responders.</description>
        <time_frame>Week 16</time_frame>
        <population>Analysis was performed on FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupilumab 300 mg qw</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.</description>
          </group>
          <group group_id="O2">
            <title>Dupilumab 300 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O3">
            <title>Dupilumab 200 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O4">
            <title>Dupilumab 300 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O5">
            <title>Dupilumab 100 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved IGA Score Reduction of ≥2 at Week 16</title>
          <description>IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic success is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score reduction from baseline of ≥2 points at Week 16 were reported. Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as a non-responders.</description>
          <population>Analysis was performed on FAS.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" lower_limit="37.89" upper_limit="63.62"/>
                    <measurement group_id="O2" value="46.9" lower_limit="34.28" upper_limit="59.77"/>
                    <measurement group_id="O3" value="42.6" lower_limit="30.04" upper_limit="55.94"/>
                    <measurement group_id="O4" value="35.4" lower_limit="23.92" upper_limit="48.23"/>
                    <measurement group_id="O5" value="20.0" lower_limit="11.10" upper_limit="31.77"/>
                    <measurement group_id="O6" value="9.8" lower_limit="3.70" upper_limit="20.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Peak Weekly Averaged Pruritus Numerical Rating Scores (NRS) From Baseline to Week 16</title>
        <description>Pruritus NRS is an assessment tool that is used to report the intensity of participant’s pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 – 10 [0 = no itch; 10 = worst itch imaginable]).</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Analysis was performed on FAS. Here, number of participants analyzed = participants with pruritus NRS assessment at specified time-point. Efficacy data was set to missing after use of rescue medication. Missing values imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupilumab 300 mg qw</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.</description>
          </group>
          <group group_id="O2">
            <title>Dupilumab 300 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O3">
            <title>Dupilumab 200 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O4">
            <title>Dupilumab 300 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O5">
            <title>Dupilumab 100 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Peak Weekly Averaged Pruritus Numerical Rating Scores (NRS) From Baseline to Week 16</title>
          <description>Pruritus NRS is an assessment tool that is used to report the intensity of participant’s pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 – 10 [0 = no itch; 10 = worst itch imaginable]).</description>
          <population>Analysis was performed on FAS. Here, number of participants analyzed = participants with pruritus NRS assessment at specified time-point. Efficacy data was set to missing after use of rescue medication. Missing values imputed by LOCF.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.85" spread="31.368"/>
                    <measurement group_id="O2" value="-46.22" spread="31.964"/>
                    <measurement group_id="O3" value="-40.6" spread="33.073"/>
                    <measurement group_id="O4" value="-38.69" spread="38.366"/>
                    <measurement group_id="O5" value="-21.47" spread="32.952"/>
                    <measurement group_id="O6" value="-0.43" spread="38.423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Peak Weekly Averaged Pruritus NRS From Baseline to Week 16</title>
        <description>Pruritus NRS is an assessment tool that is used to report the intensity of participant’s pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 – 10 [0 = no itch; 10 = worst itch imaginable]).</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Analysis was performed on FAS. Here, number of participants analyzed =participants with pruritus NRS assessment at specified time-points. Efficacy data was set to missing after use of rescue medication. Missing values imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupilumab 300 mg qw</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.</description>
          </group>
          <group group_id="O2">
            <title>Dupilumab 300 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O3">
            <title>Dupilumab 200 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O4">
            <title>Dupilumab 300 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O5">
            <title>Dupilumab 100 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Peak Weekly Averaged Pruritus NRS From Baseline to Week 16</title>
          <description>Pruritus NRS is an assessment tool that is used to report the intensity of participant’s pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 – 10 [0 = no itch; 10 = worst itch imaginable]).</description>
          <population>Analysis was performed on FAS. Here, number of participants analyzed =participants with pruritus NRS assessment at specified time-points. Efficacy data was set to missing after use of rescue medication. Missing values imputed by LOCF.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="63"/>
                    <count group_id="O5" value="64"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.54" spread="1.54"/>
                    <measurement group_id="O2" value="6.74" spread="2.072"/>
                    <measurement group_id="O3" value="6.98" spread="2.315"/>
                    <measurement group_id="O4" value="6.84" spread="1.853"/>
                    <measurement group_id="O5" value="6.71" spread="1.882"/>
                    <measurement group_id="O6" value="6.34" spread="1.832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="61"/>
                    <count group_id="O4" value="64"/>
                    <count group_id="O5" value="65"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.07" spread="2.148"/>
                    <measurement group_id="O2" value="3.64" spread="2.388"/>
                    <measurement group_id="O3" value="4.21" spread="2.763"/>
                    <measurement group_id="O4" value="3.99" spread="2.449"/>
                    <measurement group_id="O5" value="5.26" spread="2.465"/>
                    <measurement group_id="O6" value="6.05" spread="2.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="63"/>
                    <count group_id="O5" value="64"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.48" spread="2.32"/>
                    <measurement group_id="O2" value="-3.16" spread="2.467"/>
                    <measurement group_id="O3" value="-2.77" spread="2.595"/>
                    <measurement group_id="O4" value="-2.79" spread="2.609"/>
                    <measurement group_id="O5" value="-1.46" spread="2.038"/>
                    <measurement group_id="O6" value="-0.27" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in EASI Score From Baseline to Week 16</title>
        <description>The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Analysis was performed on FAS. Here, number of participants analyzed = participants with EASI score assessment at specified time-points. Efficacy data was set to missing after use of rescue medication. Missing values imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupilumab 300 mg qw</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.</description>
          </group>
          <group group_id="O2">
            <title>Dupilumab 300 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O3">
            <title>Dupilumab 200 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O4">
            <title>Dupilumab 300 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O5">
            <title>Dupilumab 100 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in EASI Score From Baseline to Week 16</title>
          <description>The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.</description>
          <population>Analysis was performed on FAS. Here, number of participants analyzed = participants with EASI score assessment at specified time-points. Efficacy data was set to missing after use of rescue medication. Missing values imputed by LOCF.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="61"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="65"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" spread="11.23"/>
                    <measurement group_id="O2" value="33.8" spread="14.52"/>
                    <measurement group_id="O3" value="32.9" spread="15.5"/>
                    <measurement group_id="O4" value="29.4" spread="11.48"/>
                    <measurement group_id="O5" value="32.2" spread="13.49"/>
                    <measurement group_id="O6" value="32.9" spread="13.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="64"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="8.83"/>
                    <measurement group_id="O2" value="10.7" spread="12.89"/>
                    <measurement group_id="O3" value="10.9" spread="12.41"/>
                    <measurement group_id="O4" value="9.8" spread="11.16"/>
                    <measurement group_id="O5" value="17.4" spread="15.28"/>
                    <measurement group_id="O6" value="25.6" spread="18.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="64"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.1" spread="1.70"/>
                    <measurement group_id="O2" value="-21.1" spread="1.68"/>
                    <measurement group_id="O3" value="-20.7" spread="1.71"/>
                    <measurement group_id="O4" value="-20.4" spread="1.62"/>
                    <measurement group_id="O5" value="-13.8" spread="1.64"/>
                    <measurement group_id="O6" value="-5.8" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in SCORing Atopic Dermatitis (SCORAD) Scores From Baseline to Week 16</title>
        <description>SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23–31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Analysis was performed on FAS. Here, number of participants analyzed = participants with SCORAD score assessment at specified time-points. Missing values imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupilumab 300 mg qw</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.</description>
          </group>
          <group group_id="O2">
            <title>Dupilumab 300 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O3">
            <title>Dupilumab 200 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O4">
            <title>Dupilumab 300 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O5">
            <title>Dupilumab 100 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in SCORing Atopic Dermatitis (SCORAD) Scores From Baseline to Week 16</title>
          <description>SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23–31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).</description>
          <population>Analysis was performed on FAS. Here, number of participants analyzed = participants with SCORAD score assessment at specified time-points. Missing values imputed by LOCF.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.9" spread="4.12"/>
                    <measurement group_id="O2" value="-51.2" spread="4.05"/>
                    <measurement group_id="O3" value="-46.0" spread="4.12"/>
                    <measurement group_id="O4" value="-48.8" spread="3.95"/>
                    <measurement group_id="O5" value="-26.6" spread="3.98"/>
                    <measurement group_id="O6" value="-13.8" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in SCORAD Scores From Baseline to Week 16</title>
        <description>SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23–31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Analysis was performed on FAS. Here, number of participants analyzed = participants with SCORAD score assessment at specified time-points. Missing values imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupilumab 300 mg qw</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.</description>
          </group>
          <group group_id="O2">
            <title>Dupilumab 300 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O3">
            <title>Dupilumab 200 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O4">
            <title>Dupilumab 300 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O5">
            <title>Dupilumab 100 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in SCORAD Scores From Baseline to Week 16</title>
          <description>SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23–31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).</description>
          <population>Analysis was performed on FAS. Here, number of participants analyzed = participants with SCORAD score assessment at specified time-points. Missing values imputed by LOCF.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.2" spread="2.76"/>
                    <measurement group_id="O2" value="-34.4" spread="2.71"/>
                    <measurement group_id="O3" value="-30.9" spread="2.76"/>
                    <measurement group_id="O4" value="-33.1" spread="2.64"/>
                    <measurement group_id="O5" value="-18.0" spread="2.66"/>
                    <measurement group_id="O6" value="-10.5" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in EASI Score (EASI-50, EASI-75 and EASI-90 Respectively) at Week 16</title>
        <description>The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50, EASI-75 and EASI-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% overall improvement in EASI score respectively from baseline to Week 16.</description>
        <time_frame>Week 16</time_frame>
        <population>Analysis was performed on FAS. Participants with a missing EASI score at Week 16 were treated as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupilumab 300 mg qw</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.</description>
          </group>
          <group group_id="O2">
            <title>Dupilumab 300 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O3">
            <title>Dupilumab 200 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O4">
            <title>Dupilumab 300 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O5">
            <title>Dupilumab 100 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in EASI Score (EASI-50, EASI-75 and EASI-90 Respectively) at Week 16</title>
          <description>The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50, EASI-75 and EASI-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% overall improvement in EASI score respectively from baseline to Week 16.</description>
          <population>Analysis was performed on FAS. Participants with a missing EASI score at Week 16 were treated as non-responders.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reduction of 50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.5" lower_limit="70.90" upper_limit="90.95"/>
                    <measurement group_id="O2" value="78.1" lower_limit="66.03" upper_limit="87.49"/>
                    <measurement group_id="O3" value="62.3" lower_limit="48.96" upper_limit="74.39"/>
                    <measurement group_id="O4" value="70.8" lower_limit="58.17" upper_limit="81.40"/>
                    <measurement group_id="O5" value="44.6" lower_limit="32.27" upper_limit="57.47"/>
                    <measurement group_id="O6" value="29.5" lower_limit="18.52" upper_limit="42.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduction of 75%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3" lower_limit="47.20" upper_limit="72.43"/>
                    <measurement group_id="O2" value="53.1" lower_limit="40.23" upper_limit="65.72"/>
                    <measurement group_id="O3" value="55.7" lower_limit="42.45" upper_limit="68.45"/>
                    <measurement group_id="O4" value="49.2" lower_limit="36.60" upper_limit="61.93"/>
                    <measurement group_id="O5" value="29.2" lower_limit="18.60" upper_limit="41.83"/>
                    <measurement group_id="O6" value="11.5" lower_limit="4.74" upper_limit="22.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduction of 90%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" lower_limit="24.73" upper_limit="49.60"/>
                    <measurement group_id="O2" value="29.7" lower_limit="18.91" upper_limit="42.42"/>
                    <measurement group_id="O3" value="31.1" lower_limit="19.90" upper_limit="44.29"/>
                    <measurement group_id="O4" value="29.2" lower_limit="18.60" upper_limit="41.83"/>
                    <measurement group_id="O5" value="15.4" lower_limit="7.63" upper_limit="26.48"/>
                    <measurement group_id="O6" value="3.3" lower_limit="0.40" upper_limit="11.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in SCORAD Score (SCORAD-50, SCORAD-75 and SCORAD-90 Respectively) at Week 16</title>
        <description>SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23–31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). SCORAD-50, SCORAD-75 and SCORAD-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% overall improvement in SCORAD score respectively from baseline to Week 16.</description>
        <time_frame>Week 16</time_frame>
        <population>Analysis was performed on FAS. Participants with a missing SCORAD score at Week 16 were treated as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupilumab 300 mg qw</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.</description>
          </group>
          <group group_id="O2">
            <title>Dupilumab 300 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O3">
            <title>Dupilumab 200 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O4">
            <title>Dupilumab 300 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O5">
            <title>Dupilumab 100 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in SCORAD Score (SCORAD-50, SCORAD-75 and SCORAD-90 Respectively) at Week 16</title>
          <description>SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23–31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). SCORAD-50, SCORAD-75 and SCORAD-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% overall improvement in SCORAD score respectively from baseline to Week 16.</description>
          <population>Analysis was performed on FAS. Participants with a missing SCORAD score at Week 16 were treated as non-responders.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reduction of 50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.3" lower_limit="55.3" upper_limit="79.4"/>
                    <measurement group_id="O2" value="59.4" lower_limit="46.4" upper_limit="71.5"/>
                    <measurement group_id="O3" value="52.5" lower_limit="39.3" upper_limit="65.4"/>
                    <measurement group_id="O4" value="55.4" lower_limit="42.5" upper_limit="67.7"/>
                    <measurement group_id="O5" value="26.2" lower_limit="16.0" upper_limit="38.5"/>
                    <measurement group_id="O6" value="19.7" lower_limit="10.6" upper_limit="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduction of 75%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" lower_limit="14.0" upper_limit="36.2"/>
                    <measurement group_id="O2" value="25.0" lower_limit="15.0" upper_limit="37.4"/>
                    <measurement group_id="O3" value="16.4" lower_limit="8.2" upper_limit="28.1"/>
                    <measurement group_id="O4" value="21.5" lower_limit="12.3" upper_limit="33.5"/>
                    <measurement group_id="O5" value="7.7" lower_limit="2.5" upper_limit="17.0"/>
                    <measurement group_id="O6" value="3.3" lower_limit="0.4" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduction of 90%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="1.8" upper_limit="15.5"/>
                    <measurement group_id="O2" value="6.3" lower_limit="1.7" upper_limit="15.2"/>
                    <measurement group_id="O3" value="4.9" lower_limit="1.0" upper_limit="13.7"/>
                    <measurement group_id="O4" value="3.1" lower_limit="0.4" upper_limit="10.7"/>
                    <measurement group_id="O5" value="3.1" lower_limit="0.4" upper_limit="10.7"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Patient Oriented Eczema Measure (POEM) Scores From Baseline to Week 16</title>
        <description>POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life [QOL]).</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Analysis was performed on FAS. Here, number of participants analyzed = participants with POEM score assessment at specified time-points. Missing values imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupilumab 300 mg qw</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.</description>
          </group>
          <group group_id="O2">
            <title>Dupilumab 300 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O3">
            <title>Dupilumab 200 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O4">
            <title>Dupilumab 300 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O5">
            <title>Dupilumab 100 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Patient Oriented Eczema Measure (POEM) Scores From Baseline to Week 16</title>
          <description>POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life [QOL]).</description>
          <population>Analysis was performed on FAS. Here, number of participants analyzed = participants with POEM score assessment at specified time-points. Missing values imputed by LOCF.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.3" spread="4.52"/>
                    <measurement group_id="O2" value="-44.0" spread="4.44"/>
                    <measurement group_id="O3" value="-49.2" spread="5.54"/>
                    <measurement group_id="O4" value="-46.6" spread="4.33"/>
                    <measurement group_id="O5" value="-14.2" spread="4.35"/>
                    <measurement group_id="O6" value="0.2" spread="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in POEM Scores From Baseline to Week 16</title>
        <description>POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life [QOL]).</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Analysis was performed on FAS. Here, number of participants analyzed = participants with POEM score assessment at specified time-points. Missing values imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupilumab 300 mg qw</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.</description>
          </group>
          <group group_id="O2">
            <title>Dupilumab 300 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O3">
            <title>Dupilumab 200 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O4">
            <title>Dupilumab 300 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O5">
            <title>Dupilumab 100 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in POEM Scores From Baseline to Week 16</title>
          <description>POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life [QOL]).</description>
          <population>Analysis was performed on FAS. Here, number of participants analyzed = participants with POEM score assessment at specified time-points. Missing values imputed by LOCF.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" spread="0.88"/>
                    <measurement group_id="O2" value="-9.8" spread="0.87"/>
                    <measurement group_id="O3" value="-10.4" spread="0.89"/>
                    <measurement group_id="O4" value="-9.9" spread="0.85"/>
                    <measurement group_id="O5" value="-3.3" spread="0.85"/>
                    <measurement group_id="O6" value="-1.1" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations, and Lichenification) From Baseline to Week 16</title>
        <description>Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0=none, 1=mild, 2=moderate and 3=severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Analysis was performed on FAS. Here, number of participants analyzed = participants with GISS score assessment at specified time-points. Missing values imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupilumab 300 mg qw</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.</description>
          </group>
          <group group_id="O2">
            <title>Dupilumab 300 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O3">
            <title>Dupilumab 200 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O4">
            <title>Dupilumab 300 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O5">
            <title>Dupilumab 100 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations, and Lichenification) From Baseline to Week 16</title>
          <description>Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0=none, 1=mild, 2=moderate and 3=severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).</description>
          <population>Analysis was performed on FAS. Here, number of participants analyzed = participants with GISS score assessment at specified time-points. Missing values imputed by LOCF.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.10"/>
                    <measurement group_id="O2" value="-0.9" spread="0.10"/>
                    <measurement group_id="O3" value="-0.8" spread="0.10"/>
                    <measurement group_id="O4" value="-0.8" spread="0.10"/>
                    <measurement group_id="O5" value="-0.4" spread="0.10"/>
                    <measurement group_id="O6" value="-0.2" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infiltration/Papulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.11"/>
                    <measurement group_id="O2" value="-1.1" spread="0.11"/>
                    <measurement group_id="O3" value="-1.0" spread="0.11"/>
                    <measurement group_id="O4" value="-1.1" spread="0.10"/>
                    <measurement group_id="O5" value="-0.6" spread="0.11"/>
                    <measurement group_id="O6" value="-0.3" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Excoriations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="0.11"/>
                    <measurement group_id="O2" value="-1.4" spread="0.11"/>
                    <measurement group_id="O3" value="-1.1" spread="0.11"/>
                    <measurement group_id="O4" value="-1.3" spread="0.11"/>
                    <measurement group_id="O5" value="-0.6" spread="0.11"/>
                    <measurement group_id="O6" value="-0.4" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lichenification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.12"/>
                    <measurement group_id="O2" value="-1.1" spread="0.11"/>
                    <measurement group_id="O3" value="-1.0" spread="0.12"/>
                    <measurement group_id="O4" value="-1.1" spread="0.11"/>
                    <measurement group_id="O5" value="-0.7" spread="0.11"/>
                    <measurement group_id="O6" value="-0.3" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in GISS Cumulative Score From Baseline to Week 16</title>
        <description>Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none,1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Analysis was performed on FAS. Here, number of participants analyzed = participants with GISS score assessment at specified time-points. Missing values imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupilumab 300 mg qw</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.</description>
          </group>
          <group group_id="O2">
            <title>Dupilumab 300 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O3">
            <title>Dupilumab 200 mg q2w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
          </group>
          <group group_id="O4">
            <title>Dupilumab 300 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O5">
            <title>Dupilumab 100 mg q4w</title>
            <description>Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw (when Dupilumab not administered) from Week 1 to Week 15.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in GISS Cumulative Score From Baseline to Week 16</title>
          <description>Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none,1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).</description>
          <population>Analysis was performed on FAS. Here, number of participants analyzed = participants with GISS score assessment at specified time-points. Missing values imputed by LOCF.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="0.38"/>
                    <measurement group_id="O2" value="-4.5" spread="0.37"/>
                    <measurement group_id="O3" value="-3.9" spread="0.38"/>
                    <measurement group_id="O4" value="-4.3" spread="0.37"/>
                    <measurement group_id="O5" value="-2.3" spread="0.37"/>
                    <measurement group_id="O6" value="-1.2" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Baseline to Week 32) regardless of seriousness or relationship to investigational product</time_frame>
      <desc>TEAEs that developed during the treatment and follow-up period (time period from the administration of first dose of study drug to the EOS visit [Week 32]).</desc>
      <group_list>
        <group group_id="E1">
          <title>Dupilumab 300 mg qw</title>
          <description>Participants who received 2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.</description>
        </group>
        <group group_id="E2">
          <title>Dupilumab 300 mg q2w</title>
          <description>Participants who received 2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
        </group>
        <group group_id="E3">
          <title>Dupilumab 200 mg q2w</title>
          <description>Participants who received 2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.</description>
        </group>
        <group group_id="E4">
          <title>Dupilumab 300 mg q4w</title>
          <description>Participants who received 2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.</description>
        </group>
        <group group_id="E5">
          <title>Dupilumab 100 mg q4w</title>
          <description>Participants who received 2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Participants who received 2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection every week (qw) from Week 1 to Week 15.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>meddra (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hip dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>meddra (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="38" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="16" subjects_at_risk="63"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="64"/>
                <counts group_id="E3" events="25" subjects_affected="16" subjects_at_risk="61"/>
                <counts group_id="E4" events="29" subjects_affected="21" subjects_at_risk="65"/>
                <counts group_id="E5" events="29" subjects_affected="20" subjects_at_risk="65"/>
                <counts group_id="E6" events="23" subjects_affected="16" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E5" events="8" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E6" events="11" subjects_affected="11" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="40" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E2" events="13" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E3" events="24" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E5" events="18" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="65"/>
                <counts group_id="E5" events="13" subjects_affected="11" subjects_at_risk="65"/>
                <counts group_id="E6" events="12" subjects_affected="10" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Not less than 45 days prior to submission for publication or presentation, the Institution shall, or cause the Principal Investigator to, provide the Sponsor with a copy of the Manuscript. The Institution shall consider in good faith any comments from the Sponsor regarding the content, and shall delete Confidential Information upon written request of the Sponsor. At the Sponsor’s request, the Institution shall delay publication for an additional 60 days to allow patent applications to be filed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Management</name_or_title>
      <organization>Regeneron Pharmaceuticals, Inc</organization>
      <email>clinicaltrials@regeneron.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

